Literature DB >> 10461360

Hypergastrinemia and enterochromaffin-like cell hyperplasia.

G Delle Fave1, M Marignani, A Moretti, G D'Ambra, G Martino, B Annibale.   

Abstract

UNLABELLED: The enterochromaffin-like (ECL) cells, the most frequent endocrine cells of the oxyntic mucosa of the stomach, are under the trophic stimulus of gastrin. These cells undergo a hyperplastic increase in variety of hypergastrinemic diseases. The most widely accepted nomenclature for the description of hyperplastic proliferation has been retrospectively arranged in a sequence presumed to reflect a temporal evolution of the proliferative process. A comparative, prospective study aimed to verify, in human hypergastrinemic diseases such as atrophic body gastritis (ABG), Zollinger-Ellison syndrome (ZES) and antral gastrin cell hyperfunction (AGCH), the effect of exposure of ECL cells to different pattern of gastrin hypersecretion, is lacking. To this purpose, we studied a series of consecutive patients with ABG, ZES and AGCH at the time of first diagnosis.
MATERIAL AND METHODS: The patients included in this study (124 ABG, 18 ZES and 10 AGCH) were selected on the basis of two previously performed screening studies aimed to diagnose these diseases. All patients at the time of diagnosis underwent gastroscopy, with multiple biopsies of the gastric body mucosa for the evaluation of qualitative pattern of ECL cells hyperplasia, and basal fasting gastrin determination. A sample of hypergastrinemic patients from each group was further investigated by meal-stimulation of gastrin secretion and quantitative morphometry for CgA positive gastric body endocrine cells.
RESULTS: AGCH patients showed only the normal or simple hyperplasia pattern. In the ZES group, simple and linear grades accounted for 38.4 percent and 46.1 percent, respectively. MEN-I patients showed only these two patterns. The majority of ABG patients showed the presence of micronodular pattern (59.7 percent). A correlation analysis between fasting gastrin levels and grade of hyperplasia (r = 0.5580, p < 0.0001), indicates that the greater the gastrin levels, the higher is the degree of severity of ECL hyperplasia pattern. In conclusion, our data support the role of gastrin as the selective contributor to the progression of ECL cell hyperplasia in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10461360      PMCID: PMC2578981     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  27 in total

1.  Grading and classification of chronic gastritis: one American response to the Sydney system.

Authors:  P Correa; J H Yardley
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

2.  Antral gastrin cell hyperfunction in children. A functional and immunocytochemical report.

Authors:  B Annibale; M Bonamico; G Rindi; L Villani; E Ferrante; A Vania; E Solcia; G Delle Fave
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

3.  Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease.

Authors:  B Annibale; L De Magistris; V Corleto; G D'Ambra; M Marignani; C Iannoni; G Delle Fave
Journal:  Aliment Pharmacol Ther       Date:  1994-02       Impact factor: 8.171

4.  Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis.

Authors:  R Lamberts; W Creutzfeldt; H G Strüber; G Brunner; E Solcia
Journal:  Gastroenterology       Date:  1993-05       Impact factor: 22.682

5.  Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment.

Authors:  G Cadiot; T Lehy; P Ruszniewski; S Bonfils; M Mignon
Journal:  Dig Dis Sci       Date:  1993-07       Impact factor: 3.199

6.  Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide.

Authors:  C Bordi; C Azzoni; F P Pilato; F Robutti; G D'Ambra; P Caruana; G Rindi; V D Corleto; B Annibale; G Delle Fave
Journal:  Regul Pept       Date:  1993-09-22

7.  Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth.

Authors:  W Creutzfeldt; R Lamberts
Journal:  Digestion       Date:  1992       Impact factor: 3.216

Review 8.  Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis.

Authors:  E Solcia; R Fiocca; L Villani; O Luinetti; C Capella
Journal:  Am J Surg Pathol       Date:  1995       Impact factor: 6.394

9.  Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth.

Authors:  G Ferraro; B Annibale; M Marignani; C Azzoni; T D'Adda; G D'Ambra; C Bordi; G delle Fave
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

10.  Trophic effect of gastrin on the enterochromaffin like cells of the rat stomach: establishment of a dose response relationship.

Authors:  E Brenna; H L Waldum
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more
  10 in total

Review 1.  Diagnosis of Zollinger-Ellison syndrome: increasingly difficult.

Authors:  Tetsuhide Ito; Guillaume Cadiot; Robert T Jensen
Journal:  World J Gastroenterol       Date:  2012-10-21       Impact factor: 5.742

2.  A case of mixed adenoneuroendocrine carcinoma of the stomach with focal intestinal metaplasia and hypergastrinemia.

Authors:  Hayato Yamauchi; Shinji Sakurai; Nobuhiro Nakazawa; Tomonori Yoshida; Yuichi Tabe; Kana Saitoh; Takaharu Fukasawa; Shinsuke Kiriyama; Hiroshi Naitoh; Hiroyuki Kuwano
Journal:  Int Surg       Date:  2015-03

3.  Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.

Authors:  David C Metz; Guillaume Cadiot; Pierre Poitras; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Endocr Oncol       Date:  2017-10-11

4.  Proton pump inhibitors on pancreatic cancer risk and survival.

Authors:  Malcolm D Kearns; Ben Boursi; Yu-Xiao Yang
Journal:  Cancer Epidemiol       Date:  2017-01-02       Impact factor: 2.984

Review 5.  Gastrin - active participant or bystander in gastric carcinogenesis?

Authors:  Susan A Watson; Anna M Grabowska; Mohamad El-Zaatari; Arjun Takhar
Journal:  Nat Rev Cancer       Date:  2006-12       Impact factor: 60.716

6.  A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors.

Authors:  Marc J Berna; Bruno Annibale; Massimo Marignani; Tu Vinh Luong; Vito Corleto; Andrea Pace; Tetsuhide Ito; David Liewehr; David J Venzon; Gianfranco Delle Fave; Cesare Bordi; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

Review 7.  Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.

Authors:  Marc J Berna; Robert T Jensen
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 8.  Gastrin and Gastric Cancer.

Authors:  Helge L Waldum; Liv Sagatun; Patricia Mjønes
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-17       Impact factor: 5.555

9.  Chloroacetanilide herbicide-induced rat enterochromaffin cell tumors: a case study within the context of the IPCS framework, for analyzing the relevance of a cancer mode of action for humans.

Authors:  Midori Yoshida
Journal:  J Toxicol Pathol       Date:  2021-04-02       Impact factor: 1.628

Review 10.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.